Intracranial activity of ifinatamab deruxtecan (I-DXd) in patients with extensive-stage small cell lung cancer and baseline brain metastases: Primary analysis of IDeate-Lung01

Misty D. Shields, MD, PhD, discusses new data from the phase 2 IDeate-Lung01 trial evaluating ifinatamab deruxtecan (I-DXd) in patients with extensive-stage small cell lung cancer (ES-SCLC), including those with baseline brain metastases. 

Dr. Shields highlights that I-DXd demonstrated promising systemic and intracranial activity, with high objective response rates and durable disease control across subgroups, regardless of prior brain radiotherapy. 

The findings showed strong concordance between systemic and CNS responses, suggesting meaningful intracranial efficacy and the potential for I-DXd to help prevent brain progression. 

Additionally, the safety profile of I-DXd was consistent with prior reports, with no new safety signals identified. These results support further evaluation of I-DXd in the ongoing phase 3 IDeate-Lung02 study, positioning the antibody–drug conjugate as a potential new treatment option for patients with relapsed or refractory ES-SCLC.

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Misty D. Shields, MD, PhD, reviews primary findings from the IDeate-Lung01 trial, highlighting the promising systemic and intracranial efficacy and manageable safety profile of ifinatamab deruxtecan (I-DXd) in patients with extensive-stage small cell lung cancer, including those with baseline brain metastases.